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Abstract
In previous studies we have shown that a pantothenate auxotroph of Myocbacterium bovis BCG (BCGDpanCD) expressing
HIV-1 subtype C Gag induced Gag-specific immune responses in mice and Chacma baboons after prime-boost
immunization in combination with matched rMVA and VLP vaccines respectively. In this study recombinant BCG (rBCG)
expressing HIV-1 subtype C reverse transcriptase and a truncated envelope were constructed using both the wild type BCG
Pasteur strain as a vector and the pantothenate auxotroph. Mice were primed with rBCG expressing Gag and RT and
boosted with a recombinant MVA, expressing a polyprotein of Gag, RT, Tat and Nef (SAAVI MVA-C). Priming with
rBCGDpanCD expressing Gag or RT rather than the wild type rBCG expressing Gag or RT resulted in higher frequencies of
total HIV-specific CD8+ T cells and increased numbers of T cells specific to the subdominant Gag and RT epitopes. Increasing
the dose of rBCG from 105 cfu to 107 cfu also led to an increase in the frequency of responses to subdominant HIV epitopes.
A mix of the individual rBCGDpanCD vaccines expressing either Gag, RT or the truncated Env primed the immune system for
a boost with SAAVI MVA-C and generated five-fold higher numbers of HIV-specific IFN-c-spot forming cells than mice
primed with rBCGDpanCD containing an empty vector control. Priming with the individual rBCGDpanCD vaccines or the mix
and boosting with SAAVI MVA-C also resulted in the generation of HIV-specific CD4+ and CD8+ T cells producing IFN-c and
TNF-a and CD4+ cells producing IL-2. The rBCG vaccines tested in this study were able to prime the immune system for a
boost with rMVA expressing matching antigens, inducing robust, HIV-specific T cell responses to both dominant and
subdominant epitopes in the individual proteins when used as individual vaccines or in a mix.
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Introduction
HIV infection is a major health problem in Southern Africa
and, in particular, South Africa. Even though the infection rate
appears to be stabilizing with the rollout of antiretroviral drugs,
there are still an estimated 5.5 million people living with HIV in
South Africa (11% of total population). The prevalence is higher
(17.8%) amongst 15–49 year-olds (UNAIDS) and approximately
30% of women attending ante-natal clinics in South Africa were
found to be HIV positive in 2010. The most effective way to
control such an epidemic would be by means of vaccination.
The first indication that vaccination against HIV acquisition is
possible has come from the encouraging outcome of the RV144
trial done in Thailand which has provided evidence that an HIV
vaccine can decrease the rate of HIV infection. A combination of a
canary poxvirus vector (ALVAC-HIV) expressing HIV-1 subtype
B protease and Gag, and a fusion of subtype E and B envelope
proteins with a bivalent envelope protein boost (subtype B and E;
AIDSVAX B/E), was tested in the trial. The rate of HIV infection
for participants vaccinated with the HIV vaccine combination as
opposed to a placebo was 60% lower one year after vaccination
and 31% lower at the end of three and a half years [1].
In this trial IgG binding antibodies to the variable regions 1 and
2 of the HIV-1 envelope protein were found to inversely correlate
to the rate of HIV infection, whereas binding of plasma IgA
antibodies to HIV-1 envelope directly correlated to the rate of
HIV infection [2]. However, 31% efficacy is not sufficient to
license a vaccine and thus a vaccine regimen with better protective
efficacy is required. Elite controllers of HIV-1 have been shown to
maintain highly polyfunctional, broadly directed central memory
T cells that secret high levels of soluble mediators [3]. Thus a
vaccine that induces this type of immune response should reduce
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HIV viraemia and prolong the time individuals take to progress to
full blown AIDS. Maximum induction of HIV-specific T cell
responses has been observed using heterologous prime-boost
vaccine regimens where the vaccines used to prime and boost the
immune system deliver matching antigens via a heterologous
vector. Several studies in mice and non-human primates have
indicated recombinant Mycobacterium bovis bacillus Calmette-
Guérin (rBCG) expressing HIV antigens can efficiently prime
the immune system for a heterologous boost with recombinant
modified vaccinia virus Ankara (MVA), replication-deficient
vaccinia virus (Dis), ovine atadenovirus or human adenovirus
expressing HIV antigens [4–9].
In a previous study our group compared the use of wild type
BCG Pasteur and a pantothenate auxotroph (DpanCD) as vaccine
vectors for HIV-1 subtype C Gag. When used in a prime-boost
combination with a recombinant MVA expressing a matching
Gag antigen, the rBCGDpanCD expressing Gag (rBCGpan-Gag)
primed higher Gag-specific CD8+ T cell responses than the wild
type strain and protected against a surrogate vaccinia virus
challenge [5]. In a further study we found that high levels of Gag-
specific, polyfunctional CD8+ and CD4+ T cells and anti-Gag
antibodies were induced in baboons primed with rBCGpan-Gag
and boosted with Pr55 Gag virus-like particles [10].
Vaccine safety considerations, which are of especial importance
when being used in immuno-compromised individuals, initiated
the use of the pantothenate auxotroph strain of Pasteur.
Replication of the BCG pantothenate auxtrophic strain in
macrophages in the absence of pantothenate is very restricted
and it is safer in SCID mice than the wild type strain [11]. Despite
its limited replication in vivo a candidate TB vaccine,
rBCG(DpanCD)30 prepared using the BCG pantothenate auxtroph
provided protection from challenge similar to that of the wild type
strain of BCG in guinea pigs [11].
Until recently BCG vaccination was thought to protect against
tuberculosis disease but not against infection. However, data
generated using assays that distinguish between BCG vaccination
and tuberculosis infection, have shown that BCG vaccination also
protects against TB infection [12,13]. A study carried out by the
Pediatric Tuberculosis Network European Trials group comparing
the tuberculin skin test to interferon-gamma release assays showed
that BCG vaccination may reduce the risk of latent TB infection in
children by more than 50% [14]. Thus development of BCG as a
combined vaccine against TB and HIV could be of great benefit in
preventing infants from becoming infected with TB or HIV.
As HIV-1 subtype C accounts for approximately 90% of
infections in southern Africa, a vaccine targeting this subtype is
required in South Africa. There is a need for an HIV vaccine to
induce immune responses to epitopes in several HIV antigens to
decrease the chance of immune escape. To address this plasmids
that express either HIV-1 subtype C Gag, RT or Gp120
(truncated Env) were constructed and electroporated into M. bovis
BCG Pasteur and the pantothenate auxotroph. The HIV genes
selected for the vaccines were derived from two primary HIV-1
subtype C isolates, Du422 (gag and rt gene) and Du151 (env gene).
These viral isolates have amino acid similarity to a derived South
African consensus sequence [15]. Vaccines expressing HIV
proteins based on a local consensus sequence are proposed to
improve vaccine effectiveness by counteracting HIV genetic
variability.
These recombinant BCG vaccines were tested individually in
BALB/c mice for their ability to prime the immune system for a
boost with a recombinant MVA, expressing a polyprotein of Gag,
RT, Tat and Nef and a truncated Env (SAAVI MVA-C) [16].
Phase 1 Clinical Trials are currently being carried out using a
matching DNA prime (SAAVI DNA-C) with a SAAVI MVA-C
boost [17]. The magnitude of the response to subdominant and
dominant epitopes in the expressed HIV protein were greater for
the vaccines prepared with the pantothenate auxotroph of BCG
than those vaccines prepared with the wild type. A mix of the
individual vaccines vectored by the pantothenate auxotroph vector
and expressing either Gag, RT or the truncated Env (Gp120) was
found to prime the immune system for a boost with SAAVI MVA-
C, which induced responses to subdominant and dominant
epitopes in the three HIV proteins.
Methods
Construction of recombinant BCG (rBCG) and vaccine
preparation
Wild type M. bovis BCG Pasteur 1172 P2 (BCG) (supplied by the
Statens Seruminstitut, Denmark) and M. bovis BCG mc26000
(BCGDpanCD), a pantothenic acid auxotroph strain derived from
BCG Pasteur (gift from W. R. Jacobs Jr., New York, USA), were
grown on Middlebrook 7H10 agar supplemented with 10% oleic
acid-albumin-dextrose-catalase and 0.5% glycerol (MB-7H10) or
in Middlebrook 7H9 broth supplemented with 10% OADC, 0.2%
glycerol and 0.025% tyloxapol (MB-7H9) on rollers (4 rpm) at
37uC. Kanamycin (10 mg/ml) was included in the media for
plasmid selection where required. Media was supplemented with
pantothenate (48 mg/ml) and hygromycin (50 mg/ml) for the
growth of BCGDpanCD.
The HIV-1 gag, rt and env genes used in this study were derived
from those reported by Burgers et al., (2006) [18]. The 39end of
each HIV gene was fused to nucleotides encoding a 10 amino acid
(RGPGRAFVTI) dominant BALB/c Env CD8+ T cell epitope
within the V3 region of the HIV-1 subtype B envelope (peptide H)
[19]. This allowed evaluation of the effect of the BCG vector on
immune responses to subdominant and dominant HIV epitopes.
The Escherichia coli/mycobacterial shuttle vector pEM19, that was
used in this study, was created from pCB119 (gift from W. R.
Jacobs Jr., New York) by deleting the hsp60 promoter and lysA
gene [5]. In this vector the HIV-1 gene of interest is fused to the
nucleotides encoding the 19 kDa signal sequence and placed
under the control of the mtrA promoter. The mtrA promoter is
induced upon uptake of the rBCG by macrophages [20].
The shuttle vector pHS400 [5] contained the full length HIV-1
subtype C gag gene, codon optimised for use in BCG. However,
analysis of this gene sequence revealed the existence of a number
of potential internal ribosome binding sites and start codons with
the potential to cause expression of out of frame nonsense proteins
which would place an unnecessary metabolic burden on the
mycobacterium and possibly compromise genetic stability. The gag
gene was therefore re-codon optimised to remove these unfavour-
able sequence motifs, fused to the peptide H and cloned into the
ApaI and HpaI restriction sites of plasmid pHS400 [5] generating
the shuttle vector pHS501. In all subsequent codon optimisations
any potential ribosome binding site-like sequences were removed.
The BCG codon optimised rt gene was cloned between the ApaI
and EcoRV restriction sites of pHS501, replacing the gag gene so
that it was fused to the peptide H tag to create plasmid pRC501.
The gp150 and gp120 (amino acids 1–723 and 1–488 respectively
of Du151 Env, GenBank AF544008.1) portions of the env gene
were codon optimised for expression in BCG, fused to the peptide
H tag and cloned between the ApaI and HpaI restriction sites of
plasmid pHS400, creating plasmids pHS151 and pHS121
respectively.
The shuttle vectors pHS501, pRC501, pHS121, pHS151 and
pCONEPI (vector which does not contain any HIV genes,
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Genbank accession DQ191755) were introduced into BCG and
BCGDpanCD by standard mycobacterial electroporation proce-
dures [21]. All the rBCG vaccine stocks were prepared as
described previously [5].
Assessment of in vitro and in vivo genetic stability of the
rBCG
To confirm in vitro genetic stability plasmid DNA was recovered
from rBCG vaccine stocks and mapped with restriction enzymes.
The HIV-1 genes from two plasmids per rBCG were also
sequenced. In vivo stability was determined by the recovery of
rBCG colonies from spleens of mice 6 weeks after immunization.
Spleens were homogenized and plated on MB-7H10 medium
containing the appropriate supplements. The plates were incu-
bated at 37uC for 3–4 weeks and the rBCG colonies were then
counted. To assess the genetic integrity of the rBCG as a measure
of in vivo genetic stability, plasmid DNA was isolated from at least
40 colonies and the integrity determined using restriction enzyme
digestion. The HIV genes of two plasmids from each rBCG were
sequenced to confirm that no mutations had occurred.
Mouse immunization
The vaccination schedule and all the procedures using female
BALB/c mice (8–10 weeks old in groups of 5) were approved by
the UCT Animal Ethics Committee (reference UCTAEC 07–107)
and performed by a trained animal technologist. The individual
rBCG vaccines or the rBCG-control vaccines were tested at doses
of either 16107 cfu or 16105 cfu. A vaccine mix was prepared
using 16107 cfu each of BCGDpanCD[pHS501], (rBCGpan-Gag);
BCG [pRC501], rBCGpan-RT; and BCG -
panCD[pHS121] rBCGpan-gp120, then tested using a total dose
of 36107 cfu. A dose of 36107 cfu of the rBCGpan-Control
vaccine was used as the control for the vaccine mix. Mice were
primed by intraperitoneal injection of 200 ml of the rBCG vaccine
then boosted with rMVA [16] (104 pfu/100 ml PBS), given on day
28 as an intramuscular injection, with 50 ml injected into the
quadriceps muscles.
Preparation of splenocytes for immune assays
Spleens were harvested and pooled from 5 mice per group
12 days after the rMVA booster vaccination on day 40. A single
cell suspension of splenocytes was prepared then treated with
erythrocyte lysing buffer (0.15 M NH4Cl, 10mM KHCO3,
0.1 mM Na2EDTA) for 1 min at room temperature before
suspension in R10 culture medium (RPMI with 10% heat
inactivated fetal calf serum (FCS) containing 15 mM b-mercap-
toethanol, 100 U penicillin and 100 mg streptomycin/ml, (Invitro-
gen, Carlsbad, California, USA)).
IFN-c and IL-2 ELISPOT assays
The Mouse IFN-c and IL-2 ELISPOT sets (BD Pharmingen,
The Scientific Group, Johannesburg, SA) were used as per
manufacturer’s instructions. Splenocytes were plated at 16105/
well in a 200 ml final volume of R10 alone (to determine
background response) or medium containing 4ug/ml of an
individual peptide (.95% HPLC pure, Bachem AG, Bubendorf,
Switzerland) with amino acid sequence matching BALB/c CD8+
and CD4+ epitopes in Gag, RT and Env. For all the vaccines,
responses to the dominant CD8+ T cell epitope tag (peptide H)
were monitored using the peptide RGPGRAFVTI. Peptides with
amino acid sequences AMQMLKDTI (Gag CD8+ peptide),
NPPIPVGRIYKRWIILGLNK (Gag CD4+(13) peptide),
FRDYVDRFFKTLRAEQATQE (Gag CD4+(17) peptide),
VYYDPSKDLIA (RT CD8+ peptide), PKVKQWPLTEVKI-
KALTAI (RT CD4+ peptide), and YGVPVWREAKTTLFCA
(Env CD4+(6) peptide) were included in the assays to monitor
responses to subdominant epitopes in the respective HIV proteins
[22–24]. Reactions were stopped after a 22 hour incubation at
37uC in 5% CO2, and spots were reacted with the detection
antibody then developed with Nova Red as per the kit instructions.
Spots were counted and analysed using an automatic ELISPOT
reader (CTL technologies, Cleveland, Ohio) and Immunospot
Version 3.2 software. Average spot numbers were calculated for
triplicate reactions. For all experiments the coefficient of variation
of the average (standard deviation (SD) of the average expressed as
a percentage of the average spot numbers) was not more than 8%.
Average spot numbers for responses to peptides that were twice
that of average background spot numbers (absence of peptide)
were considered positive. Values below this cut off were set to zero.
Positive spot numbers were then adjusted to spot forming units
(sfu) per 106 splenocytes after background subtraction (not more
than 30 sfu/106 splenocytes). Cumulative IFN-c ELISPOT
responses were calculated as the sum of the responses to the
individual subdominant Gag CD8+ and CD4+ peptides and
dominant peptide H tag for the rBCG vaccines that expressed Gag
or the sum of the responses to individual subdominant RT CD8+
and CD4+ peptides and dominant peptide H for the rBCG
vaccines that expressed RT. When a mix of the individual rBCG
vaccines was tested cumulative IFN-c ELISPOT responses to Gag,
RT and Env were calculated as the sum of the peptide responses to
the individual CD8+ and CD4+ T cell epitopes in these proteins
and the response to the dominant peptide H tag. All experiments
were carried out on pooled spleens (n = 5) and in triplicate.
Quantification of secreted cytokines
Splenocytes at a concentration of 7.56106 per ml R10 culture
medium were cultured (48 h at 37uC in 5% CO2) in the absence of
peptide (to detect background cytokine release) or with the
individual peptides as used in the IFN-c ELISPOT assay at 4 mg/
ml. The cytokine content of culture supernatants was assayed
using a cytokine bead array assay (BD Pharmingen, The Scientific
Group, Johannesburg, SA) that detected IFN-c, TNF-a, IL-6 and
IL-10. The average of triplicate values was calculated and
expressed as pg cytokine per 106 splenocytes. The coefficient of
variation of the average value (SD of the average expressed as a
percentage of the average) was not more than 11%. Cytokine
values were reported after background subtraction. For all mouse
groups the average background cytokine release in the absence of
peptide was not more than 361 pg per 106 splenocytes. All
experiments were carried out on pooled spleens (n = 5) and in
triplicate.
MHC class I peptide pentameric complex binding
APC-conjugated H-2Kd MHC class I pentameric complexes
folded with the Gag peptide, AMQMLKDTI or the RT peptide
VYYDPSKDLIA and H-2Dd MHC class I pentameric complexes
folded with peptide H, RGPGRAFVTI were purchased from
ProImmune (Oxford, UK). Aliquots of splenocytes (56106) pooled
from groups of five mice were suspended in fluorescence-
associated cell-sorting (FACS) buffer [phosphate-buffered saline
(PBS) containing 1% FCS, and 0.02% NaN3] and labelled for
30 min at 4uC with the APC-conjugated pentameric complexes
and PerCP-conjugated anti-CD8a (clone 53–6.7, eBiosciences,
USA). Flow cytometric analysis was performed using a FACSca-
libur flow cytometer with Cell-Quest software (BD Biosciences).
Pentamer-reactive cells were expressed as a percentage of gated
CD8+ cells and presented as the average value of triplicates for a
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single experiment [25]. The coefficient of variation of the average
value (SD of the average expressed as a percentage of the average)
was less than 0.01%.
Statistical analysis
Results are expressed as mean and standard deviation of the
mean of the indicated number of experiments. Data was
statistically analysed using Student’s t test and p values of ,0.05
were considered significant.
Results
Selection of genetically stable rBCG vaccines
In vivo and in vitro instability of recombinant BCG, especially
those utilizing episomal vectors, is sometimes a problem.
BCG[pHS501] (rBCG-Gag), BCG [pHS501] (rBCGpan-
Gag), BCG[pRC501] (rBCG-RT) and BCG [pRC501]
(rBCGpan-RT) were all found to be stable in vitro. However, no
stable recombinants expressing the HIV-1 gp150 gene could be
obtained in either strain of BCG. In vitro stable recombinants of
both strains of BCG expressing the truncated HIV-1 gp120 gene
were obtained (rBCG-gp120 and rBCGpan-gp120).
To assess in vivo stability rBCG-Gag, rBCGpan-Gag, rBCG-RT,
rBCGpan-RT, rBCG-gp120, rBCGpan-gp120, rBCG-Control
and rBCGpan-Control were isolated from the spleens of mice 6
weeks post vaccination and plated on MB-7H10 containing the
appropriate supplements but lacking kanamycin. Plasmid DNA
was isolated from at least 40 colonies for each recombinant and
mapped with restriction enzymes. In addition the HIV genes were
sequenced from 2 plasmids of each of the rBCG. All these
recombinant BCG found to be stable in vitro remained stable in vivo
(Figure 1).
Use of a pantothenate auxotroph of BCG improves the
priming ability of the rBCG vaccine
The influence of BCG or BCGDpanCD vectors as well as rBCG
dose on immune responses to the HIV insert was evaluated by
priming mice with doses of 107 cfu or 105 cfu of rBCG-Gag,
rBCGpan-Gag, rBCG-RT, rBCGpan-RT or the respective
rBCG-Control or rBCGpan-Control vaccine followed by a rMVA
(104 pfu) boost on day 28. Responses to subdominant Gag and RT
CD8+ and CD4+ T cell epitopes and the dominant peptide H
CD8+ T cell epitope tag were assayed on day 40 using the
respective peptides in an IFN-c ELISPOT assay (Figure 2 and
Figure 3). In this study the dominant (as opposed to a
subdominant) epitope response was considered to be one that
provoked the most intense immune response.
Responses to Gag and RT CD8+ and CD4+ T cell peptides and
the peptide H CD8+ T cell peptide for a rMVA vaccination alone
were similar to that for a rBCG-Control or rBCGpan-Control
prime (107 cfu or 105 cfu) and rMVA boost. Thus the vectors had
no adjuvant activity (107 cfu or 105 cfu) or damping on HIV
peptide responses (Figure 2 and Figure 3).
Similar peptide H-specific CD8+ T cell IFN-c ELISPOT
responses of 978 to1220 sfu/106 splenocytes, that were 3-fold
above control values (p,0.01), were observed in response to
priming with either rBCG-Gag or rBCGpan-Gag (107 cfu and
105 cfu) (Figure 2A). Cumulative Gag-specific CD8+ T cell and
CD4+ T cell IFN-c ELISPOT responses, 3–4 fold above that of
control values (p,0.05), of 324 sfu/106 splenocytes and 516 to
701 sfu/106 splenocytes, was achieved by priming with either
rBCG-Gag (107 cfu) or rBCGpan-Gag (105 cfu and 107 cfu)
respectively. The cumulative Gag-specific IFN-c ELISPOT
responses induced by rBCGpan-Gag, although not influenced by
dose, were significantly greater (p,0.05) from that induced by a
prime with rBCG-Gag (107 cfu) (Figure 2A). Subdominant Gag-
specific responses contributed 24% or 35% to the total IFN-c
ELISPOT response for a rBCG-Gag (107 cfu) prime or rBCGpan-
Gag (107 cfu or 105 cfu) prime respectively (Figure 2A). Thus
using BCGDpanCD rather than BCG as the vector allows the
induction of higher responses to subdominant Gag epitopes with
the dose having minimal influence on the magnitude of the
response to the Gag insert.
Figure 1. Schematic map and restriction enzyme digests of pHS501, pRC501 and pHS121 plasmid DNA isolated from rBCG. (A)
Schematic map of E. coli/mycobacterial shuttle vector. (B) Lanes 1 & 8 contain the molecular weight marker GeneRulerTM 1 kb Ladder (Fermentas,
S.A.). Lanes 2 & 3 contain pHS501 plasmid DNA. Lanes 4 & 5 contain pRC501 plasmid DNA. Lanes 6 & 7 contain pHS121 plasmid DNA. Lanes 2, 4 & 6
contain plasmid DNA isolated prior to transformation into BCG (positive controls). Lanes 3, 5 & 7 contain plasmid DNA isolated from rBCG. Plasmid
DNA in lanes 2 to 7 was digested with restriction enzymes XbaI and HpaI. Results were the same for rBCG and rBCGDpanCD. Enzymatic restriction
analysis of only 2 representative samples are shown for each rBCG, however plasmid DNA was isolated from a minimum of 20 of each rBCG.
doi:10.1371/journal.pone.0071601.g001
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Figure 2. Influence of vector on IFN-c ELISPOT responses to a rBCG-Gag or rBCGpan-Gag prime and rMVA boost. Groups of mice were
primed with the indicated rBCG vaccines (107 cfu or 105 cfu) and then boosted with rMVA (104 pfu) on day 28. One group of mice was left
unvaccinated then vaccinated on day 28 with rMVA. On day 40 spleens were harvested and splenocytes pooled from 5 mice per group. (A) IFN-c
ELISPOT assays with Gag CD8+ T cells and CD4+ T cell peptides or peptide H CD8+ T cell peptide. Bars are the average and standard deviation of the
average IFN-c ELISPOT responses for the indicated individual peptides for 3 separate experiments. Asterisks indicate statistical significance of the
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A single experiment was performed using H-2Kd and H-2Dd
MHC class I pentamers folded with the Gag CD8+ T cell peptide
or the peptide H CD8+ T cell peptide respectively to directly
enumerate Gag- and peptide H-specific CD8+ T cells as a
percentage of total gated CD8+ T cells (Figure 2B). Cumulative
frequencies of Gag- and peptide H-specific CD8+ T cells of not
more than 1.3% of the total CD8+ T cell population was induced
by a rBCG-Control prime or rBCGpan-Control prime (107 cfu or
105 cfu) and rMVA boost which was not different from a rMVA
vaccination alone (Figure 2B).
A rBCGpan-Gag (107 cfu and 105 cfu) prime induced more
peptide H-specific CD8+ T cells than the respective rBCG-Gag
prime (p,0.01). In addition, priming with rBCGpan-Gag resulted
in higher cumulative frequencies of Gag- and peptide H-specific
CD8+ T cells (9.4% and 13.1% of the total CD8+ T cells for a dose
of 107 cfu and 105 cfu respectively) than rBCG-Gag (3% and
4.7% for a dose of 107 cfu and 105 cfu respectively). Priming with
105 cfu of rBCG-Gag or rBCGpan-Gag induced significantly
(p,0.01) higher peptide H-specific CD8+ T cells than doses of
107 cfu (Figure 2B). Subdominant Gag-specific CD8+ T cells were
only observed with a rBCGpan-Gag prime, these CD8+ T cells
contributed 7.2% (107 cfu) and 4.3% (105 cfu) to the respective
cumulative frequencies (Figure 2B).
The choice of vector for expression of RT did not influence RT-
and peptide H-specific CD8+ T cell IFN-c ELISPOT responses.
Peptide H-specific CD8+ T cell IFN-c ELISPOT magnitudes of
629 to 1000 sfu/106 splenocytes, that were 3-fold above control
values (p,0.01 or p,0.05), and RT-specific CD8+ T cell
magnitudes of 530 to 730 sfu/106 splenocytes that were 5-fold
above control values (p,0.01), were observed after priming with
either rBCG-RT or rBCGpan-RT (107 cfu and 105 cfu)
(Figure 3A). No RT-specific CD4+ T cell peptide responses above
control values were induced by a rBCG-RT prime. In contrast,
priming with rBCGpan-RT (107 cfu and 105 cfu) induced similar
RT CD4+ T cell IFN-c ELISPOT responses of 235 to 240 sfu/106
splenocytes that were 2-fold above control values (p,0.05). Thus
the advantage of priming with BCGpan-RT as opposed to rBCG-
RT prior to the rMVA boost is the induction of subdominant RT
CD4+ T cell peptide responses.
A further single experiment using H-2Kd and H-2Dd MHC
class I pentamers folded with the RT CD8+ T cell peptide or the
peptide H CD8+ T cell peptide respectively was performed to
directly enumerate RT CD8+ T cell and peptide H CD8+ T cell
frequencies as a percentage of total gated CD8+ T cells (Figure 3B).
Cumulative RT- and peptide H-specific CD8+ T cell frequencies
induced by either a rBCG-Control or rBCGpan-Control prime
(107 cfu or 105 cfu) and rMVA boost or rMVA vaccination alone
were not significantly different and were not more than 1.3% of
the total CD8+ T cell population (Figure 3B). The choice of vector
(either BCG or BCGDpanCD) for RT did not influence the
frequency of peptide H-specific CD8+ T cells. However RT-
specific CD8+ T cell frequencies induced by priming with
rBCGpan-RT prime were significantly higher (p,0.01) than for
a respective rBCG-RT prime. Cumulative RT- and peptide H-
specific CD8+ T cell frequencies reached approximately 3.3% of
the total CD8+ cells for a rBCG-RT (107 cfu or 105 cfu) prime
with 23% of the response from responding RT-specific CD8+ T
cells (Figure 3B). In contrast for a rBCGpan-RT (107 cfu or
105 cfu) prime cumulative RT- and peptide H-specific CD8+ T
cell frequencies reached approximately 5.0% of total CD8+ T cells
with 40% of the response being from RT-specific CD8+ T cells
(Figure 3B). Thus using BCGDpanCD as a vector rather than BCG
for RT expression is advantageous in influencing the level of
subdominant RT-specific CD8+ T cell frequencies. The priming
dose did not significantly influence the magnitude of the response
(Figure 3B).
Immune responses to HIV-1 Gag, RT and Env can be
achieved when a mixture of the rBCGDpanCD vaccines
are used
The need for an HIV vaccine to induce responses to several
HIV antigens led us to investigate induction of immune responses
in mice to a prime with a mix of rBCG vaccines each expressing
Gag, RT or Gp120. The BCGDpanCD vector rather than the wild
type BCG vector was used for these studies as we found it primed
responses to subdominant HIV epitopes (see previous section).
A dose of 107 cfu of each individual vaccine was mixed to
provide a vaccine mix with a dose of 36107 cfu in the injection
volume. Mice were primed with this dose of vaccine mix then
boosted with rMVA (104 pfu) on day 28. The experiment also
included a prime with each of the individual vaccines (107 cfu) and
rMVA boost on day 28 for comparison purposes. Priming with the
rBCGpan-Control (107 cfu or 36107 cfu) followed by a rMVA
(104 pfu) boost on day 28 was used as a control. Splenocytes were
collected on day 40 and used in IFN-c and IL-2 ELISPOT assays
with peptide H, the CD8+ T cell epitope tag on each HIV protein,
and peptides to CD8+ T and CD4+ T cell epitopes in Gag, RT
and Gp120 to determine the immune response. The results shown
are from three separate experiments.
Cumulative IFN-c (503615 sfu/106 splenocytes) and IL-2
ELISPOT (108618 sfu/106 splenocytes) peptide responses for a
rBCGpan-Control (36107 cfu) prime and rMVA boost were not
significantly different from cumulative IFN-c (597635 sfu/106
splenocytes) and IL-2 (98619 sfu/106 splenocytes) ELISPOT
responses for a rMVA vaccination alone. Thus using a dose of
36107 cfu did not induce any adverse effect on HIV peptide
responses in the ELISPOT assays.
The vaccine mix did prime the immune system for a rMVA
boost (Figure 4A and B). Cumulative responses to Gag-, RT- and
peptide H-specific CD8+ and Gag-, RT- and Env-specific CD4+ T
cell peptides in the IFN-c ELISPOT assay reached 1798652 sfu/
106 splenocytes, approximately 3.5-fold (p,0.01) above that for
responses to these peptides induced by the BCGpan-Control
prime and rMVA boost (Figure 4A). Subdominant Gag- and RT-
specific CD8+ T cell and Gag-, RT- and Env-specific CD4+ T cell
responses contributed 66% to the cumulative response for a prime
with the vaccine mix. Cumulative magnitudes of the IFN-c
mean IFN-c ELISPOT responses for the individual peptides for a rBCG-Gag or rBCGpan-Gag vaccine prime and rMVA boost compared to that for the
respective rBCG-Control or rBCGpan-Control vaccine prime and rMVA boost. (B) Splenocytes were stained with H-2Kd and H-2Dd MHC class I
pentamers folded with the Gag CD8+ T cell peptide or peptide H CD8+ T cell peptide and flow cytometry was used to determine the frequency of
Gag- and peptide H-specific CD8+ T cells in the splenocyte population. Bars are the average of triplicate values for Gag- and peptide H-specific CD8+ T
cells expressed as a percentage of the total gated CD8+ T cell population for a single experiment. The coefficient of variation of all average values
(standard deviation of the average expressed as a percentage of the average) was less than 0.01%. Asterisks indicate the statistical significance of the
mean values for the percentage of Gag- or peptide H-specific CD8+ T cells for a rBCG-Gag or rBCGpan-Gag vaccine prime and rMVA boost compared
to that for the respective rBCG-Control or BCGpan-Control vaccine prime and rMVA boost. Respective differences for peptide responses between
groups are also indicated. *,0.01; **,0.05; Student’s t-test for means of unpaired data.
doi:10.1371/journal.pone.0071601.g002
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Figure 3. Influence of vector on IFN-c ELISPOT responses to a rBCG-RT or rBCGpan-RT prime and rMVA boost. Groups of mice were
primed with the indicated rBCG vaccines (107 cfu or 105 cfu) then boosted with rMVA (104 pfu) on day 28. One group of mice was left unvaccinated
then vaccinated on day 28 with rMVA. On day 40 spleens were harvested and splenocytes pooled from 5 mice per group. (A) IFN-c ELISPOT assays
with RT CD8+ T cell and CD4+ T cell peptides or peptide H CD8+ T cell peptide. Bars are the average and standard deviation of the average IFN-c
ELISPOT responses for the indicated individual peptides for 3 separate experiments. Asterisks indicate statistical significance of the mean IFN-c
ELISPOT responses for the individual peptides for a rBCG-RT or rBCGpan-RT vaccine prime and rMVA boost compared to that for the respective BCG-
Control or rBCGpan-Control vaccine prime and rMVA boost. (B) Splenocytes were stained with H-2Kd and H-2Dd MHC class I pentamers folded with
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ELISPOT peptide responses induced by the vaccine mix did not
reach the sum of responses induced by the individual vaccines
(Figure 4A). Priming with the individual rBCGpan-Gag,
rBCGpan-RT or rBCGpan-gp120 vaccines induced cumulative
IFN-c ELISPOT CD8+ T cell and CD4+ T cell peptide responses
of 14316151 sfu/106 splenocytes; 21096185 sfu/106 splenocytes;
and 1173694 sfu/106 splenocytes respectively. These responses
are between 3.5 and 5.2 fold (p,0.01) above that for a rBCGpan-
Control prime (Figure 4A). Subdominant responses contributed
38%, 55% and 20% to the cumulative IFN-c ELISPOT CD8+ T
cell and CD4+ T cell peptide responses for the respective
individual rBCGpan vaccine prime and rMVA boost. Thus it
appears that the proportion of subdominant peptide-specific
responses to the cumulative IFN-c ELISPOT response can be
increased from an average of 37617% for an individual vaccine
prime to 66% when a vaccine mix is used as the prime.
IL-2 ELISPOT assays indicated only HIV-specific CD4+ T cells
produced IL-2 in response to a prime with either the vaccine mix
or the individual vaccines (Figure 4B). Cumulative IL-2 ELISPOT
responses to Gag, RT and Env CD4+ T cell peptides in response
to a vaccine mix prime reached 356 sfu/106 splenocytes which
was 3-fold (p,0.05) above that for responses to these peptides
induced by priming with the rBCGpan-Control. These frequen-
cies of HIV-specific IL-2 producing cells were similar to that
induced by a prime with the individual vaccines (Figure 4B).
Th1 cytokine production
The Th1/Th2 bias of the immune response to a prime with the
individual vaccines (107 cfu) or a mix of the individual vaccines
rBCGpan-Gag, rBCGpan-RT and rBCGpan-gp120 (36107 cfu)
and rMVA boost was investigated (Figure 5). rBCGpan-Control
(107 or 36107 cfu) was used as the control vaccine prime. Th1 and
Th2 cytokines were quantified in the supernatant collected from
splenocytes cultured with Gag, RT and peptide H CD8+ T cell
peptides and Gag, RT and Env CD4+ T cell peptides. No IL-10 or
IL-4 could be detected in the supernatants for a prime with the
vaccine mix and rMVA boost as well as a prime with the
individual vaccines and rMVA boost.
A prime with the vaccine mix and rMVA boost induced
peptide-specific IFN-c and TNF-a in the culture supernatants in
response to stimulation with Gag, RT and peptide H CD8+ T cell
and Gag, RT and Env CD4+ T cell peptides. These individual
peptide-specific IFN-c and TNF-a levels were significantly
different (p,0.01 or p,0.05) from the rBCGpan-Control prime
and rMVA boost (Figure 5). Cumulative HIV peptide-specific
IFN-c levels of 32696198 pg/106 splenocytes and TNF-a of
6556150 pg/106 splenocytes were measured for a vaccine mix
prime and rMVA boost which were 5 fold (p,0.01) and 3 fold
(p,0.05) higher respectively than for a rBCGpan-Control prime
and rMVA boost (Figure 5A and B). These IFN-c and TNF-a
levels, for a rBCGpan-Control prime and rMVA boost, were not
significantly different from a rMVA vaccination alone. For a
vaccine mix prime and rMVA boost 48% of the total IFN-c was
produced by subdominant peptide-specific CD8+ and CD4+ T
cells. The total TNF-a production was comprised of 85% from
subdominant peptide-specific CD8+ and CD4+ T cells. The
cumulative magnitudes of CD8+ T cell and CD4+ T cell peptide-
specific IFN-c and TNF-a for a vaccine mix prime and rMVA
boost were lower than the sum of these responses for a prime with
the individual vaccines and rMVA boost (Figure 5A and B). A
prime with the individual rBCGpan-Gag, rBCGpan-RT or
rBCGpan-gp120 vaccines and rMVA boost induced cumulative
HIV-peptide specific IFN-c magnitudes of 31826102 pg/106
splenocytes, 27456120 pg/106 splenocytes and 27136110 pg/
106 splenocytes that were 4.5 to 8 fold (p,0.01) higher respectively
than a rBCGpan-Control prime and rMVA boost (Figure 5A).
Subdominant peptide-specific CD8+ and CD4+ T cells contributed
21%, 43% and 18% to the total IFN-c production for the
respective individual rBCGpan vaccine prime and rMVA boost
(Figure 5A).
Cumulative peptide-specific TNF-a levels of 333628 pg/106
splenocytes, 440632 pg/106 splenocytes and 315615 pg/106
splenocytes induced by a prime with the individual rBCGpan-
Gag, rBCGpan-RT or rBCGpan-gp120 vaccines and rMVA
boost, were at least 3 fold (p,0.01) greater than those from a
rBCGpan-Control prime and rMVA boost (Figure 5B). Subdom-
inant peptide-specific CD8+ and CD4+ T cells contributed 40%,
57% and 40% to the total TNF-a production for the respective
individual rBCGpan vaccine prime and rMVA boost (Figure 5B).
Thus it appears that when compared to a prime with the
individual vaccines, a vaccine mix prime and rMVA boost induces
increased subdominant peptide-specific IFN-c and TNF-a pro-
duction. The proportion of subdominant peptide-specific IFN-c to
the total peptide-specific IFN-c response increased from an
average of 27613% for an individual vaccine prime to 48%
using a vaccine mix as the prime. The contribution of
subdominant peptide-specific TNF-a to the total peptide-specific
TNF-a response increased from an average of 4569% induced by
an individual vaccine prime to 85% using a vaccine mix as the
prime.
No IL-2 production by peptide-specific CD8+ T cells could be
detected for any of the vaccine regimens. A prime with the vaccine
mix and rMVA boost induced peptide-specific IL-2 levels in the
culture supernatants in response to stimulation with Gag, RT and
Env CD4+ T cell peptides which were significantly different
(p,0.01,) from the individual peptide-specific IL-2 levels in the
culture supernatants from the rBCGpan-Control prime and
rMVA boost (Figure 5C). Cumulative HIV CD4+ T cell
peptide-specific IL-2 levels of 695622 pg/106 splenocytes were
measured for a prime with the vaccine mix and rMVA boost,
which were four fold higher (p,0.01) than those produced by a
rBCGpan-Control prime and rMVA boost (Figure 5C). The levels
of HIV peptide-specific IL-2 induced by rMVA vaccination were
not significantly different to that of a rBCGpan-Control prime and
rMVA boost. The cumulative magnitudes of CD4+ T cell peptide-
specific IL-2 for a vaccine mix prime and rMVA boost were lower
than the sum of these responses for a prime with the individual
vaccine and rMVA boost (Figure 5C). A prime with the individual
rBCGpan-Gag, rBCGpan-RT or rBCGpan-gp120 vaccines and
rMVA boost induced cumulative CD4+ T cell peptide-specific IL-
2 levels of 496632 pg/106 splenocytes, 328648 pg/106 spleno-
the RT CD8+ T cell peptide or peptide H CD8+ T cell peptide and flow cytometry was used to determine the frequency of RT- and peptide H-specific
CD8+ T cells in the splenocyte population. Bars are the average of triplicate values for RT- and peptide H-specific CD8+ T cells expressed as a
percentage of the total gated CD8+ T cell population for a single experiment. The coefficient of variation of all average values (standard deviation of
the average expressed as a percentage of the average) was less than 0.01%. Asterisks indicate the statistical significance of the mean values for the
percentage of CD8+ RT- or peptide H-specific T cells for a rBCG-RT or rBCGpan-RT vaccine prime and rMVA boost compared to that for the respective
rBCG-Control or rBCGpan-Control vaccine prime and rMVA boost. Respective differences for peptide responses between groups are also indicated.
*,0.01; **,0.05; Student’s t-test for means of unpaired data.
doi:10.1371/journal.pone.0071601.g003
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cytes and 230630 pg/106 splenocytes that were 3 fold higher
(p,0.05) than for a rBCGpan-Control prime and rMVA boost
(Figure 5C).
Discussion
Studies evaluating CD8+ T cell priming by rBCG indicate
highly functional memory T cells which are able to proliferate and
produce cytokines are generated to foreign expressed proteins [26–
29]. Several factors appear to participate in this differentiation to
antigen specific cells with a memory phenotype. Slow BCG
replication rates within phagosomes and limited levels of antigen
expression that peaks in the second weak after infection are factors
that participate in this process [5,30]. A previous study of ours
showed that a rBCGpan-Gag prime and Gag VLPs boost vaccine
regimen is highly immunogenic and induces a broad and
polyfunctional central memory T cell response in baboons [10].
Other studies by Hanke et al. have also demonstrated rBCG
effectively primes the immune system for a rMVA boost to elicit
HIV-specific T cells [6–8,31]. Thus in this study a rBCG vaccine
prime and rMVA vaccine boost regimen was chosen to investigate
maximum immune responses to rBCG vaccines expressing various
HIV proteins. The rMVA chosen for the study, SAAVI MVA-C,
which is in phase I clinical trials [17], expresses proteins identical
to that expressed by the individual rBCG vaccines tested in this
study.
Figure 4. IFN-c ELISPOT responses induced by a prime with the individual rBCG-HIV vaccines or a mix of the rBCG-HIV vaccines and
rMVA boost. Groups of mice were primed with either the individual rBCGpan-Gag, rBCGpan-RT or rBCGpan-gp120 vaccines (107 cfu) or a rBCG
vaccine mix (36107 cfu) prepared by mixing 107 cfu of the individual rBCGpan-Gag, rBCGpan-RT and rBCGpan-gp120 vaccines. Groups of mice
vaccinated with the rBCGpan-Control vaccine (107 cfu to act as control for the individual vaccine vaccinations or 36107 cfu to act as control for the
mix of the individual vaccine vaccinations) served as controls. All groups of mice were then boosted with MVA (104 pfu) on day 28. On day 40 spleens
were harvested and splenocytes pooled from 5 mice per group were used in an IFN-c ELISPOT (A) or IL-2 ELISPOT (B) assay with Gag, RT, Env and
peptide H CD8+ T cell and CD4+ T cell peptides. Bars are the average and standard deviation of the average IFN-c ELISPOT (A) or IL-2 ELISPOT
responses for the indicated individual peptides for 3 separate experiments. Statistical significance (Student’s t-test for means of unpaired data) of the
mean IFN-c ELISPOT or IL-2 ELISPOT responses for the individual peptides compared to that for the control is indicated.
doi:10.1371/journal.pone.0071601.g004
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Analysis of genetic stability is an important aspect of charac-
terization of candidate vaccines. In this study we were able to
generate genetically stable (in vivo and in vitro) rBCG and
rBCGDpanCD expressing Gag, RT or a truncated Env (Gp120).
No stable recombinants expressing the HIV-1 gp150 gene could be
obtained. Instability of rBCG expressing HIV or SIV antigens has
been reported by a number of different groups. Cayabyab et al. [4]
reported that they were unable to obtain any rBCG expressing
SIV Gp160 and rBCG expressing SIV Gp120 were unstable. Two
other groups also found that rBCG expressing truncated env genes
utilising the strong hsp60 promoter were unstable, whereas one of
the groups could obtain stable rBCG expressing Gp120 when they
used the weaker a-antigen promoter for expression [32,33]. As
suggested in a previous paper, in which we were able to improve
the stability of rBCG expressing HIV-1 Gag [5], the genetic
stability of our vaccines could be due to two factors: (i) the use of
the mtrA promoter which expresses weakly in vitro but is strongly
up-regulated after uptake by phagocytosing cells and (ii) the fusion
of the HIV antigen to the 19kDa leader sequence which transports
the protein to the surface of the mycobacteria, thus removing a
possibly toxic antigen from the mycobacterial cell.
Experiments using two different assays, the IFN-c ELISPOT
assay and enumeration of pentameric MHC class I-peptide-
specific reactive CD8+ T cells, were performed to evaluate the
influence of the vector, BCG or BCGDpanCD, on immune
responses to expressed Gag and RT. An overall conclusion from
the data obtained from the two different assays is that using
BCGDpanCD rather than BCG as a vector is beneficial for the
induction of higher frequencies of total HIV-specific T cells and
increased numbers of T cells specific to the subdominant Gag and
RT epitopes. An interesting observation using the IFN-c ELI-
SPOT assay is that the magnitude of peptide H-specific CD8+ T
cell responses (when attached to the Gag or RT protein) were not
affected by the choice of vector. In contrast using the direct
enumeration method, the magnitude of peptide H-specific CD8+
T cell frequencies (when attached to the Gag protein), were
significantly higher with BCGDpanCD as the vector with the lower
BCGpan-Gag vaccine dose eliciting higher peptide H-specific
CD8+ T cells frequencies than the higher dose. Although this was
not seen for the frequencies of peptide H attached to the RT
protein frequencies of RT CD8+ T cells when directly enumerated
were significantly higher when RT was expressed by BCGDpanCD
rather than BCG. This was not detectable using the IFN-c
ELISPOT assay. An underlying difference between the assays is
that the IFN-c ELISPOT assay detects peptide-specific cells that
respond during in vitro peptide stimulation. This recall response is
not operative in the direct enumeration assay. It is possible that by
directly enumerating peptide-specific responses, differences are
more easily detected as inhibitory and/or stimulatory products
generated during the culture conditions may influence the
magnitude of responses. In addition the finding that peptide H-
specific CD8+ T cell frequencies (when attached to the Gag
protein) are greater for lower vaccine doses suggests in vivo
inflammatory conditions may affect the development of immune
responses to Gag, but possibly not affect RT immune responses.
We have shown previously [5] that BCGDpanCD is less
inflammatory than BCG which would support lower inflammatory
conditions influencing higher magnitudes of CD8+ T cells
frequencies (peptide H-specific CD8+ T cells for the BCGpan-
Gag vaccine and RT-specific CD8+ T cells frequencies for the
BCGpan-RT vaccine) using the BCGDpanCD vector.
The reason for the broader response seen with the use of the
pantothenate auxotroph as a vector over that of wild type BCG is
not clear, however it may be related to the fact that cellular
responses to immunodominant epitopes can limit responses to
subdominant epitopes [34] and the differences in in vivo
inflammatory conditions generated by BCG and BCGDpanCD.
Pantothenate is required for protection of bacteria from oxidative
stress. In addition pantothenate is a key precursor of coenzyme A
and acyl carrier proteins that are essential for many intracellular
processes including fatty acid metabolism. Lack of pantothenate
could result in an alteration in bacterial lipid metabolism and
exposure to oxidative stresses which may disrupt the survival of the
bacteria in the phagosome and promote phagosome maturation
and subsequently CD8+ T cell responses. This may operate in
conjunction with the fusion of the 19 kDa lipoprotein signal
sequence to the HIV proteins that allows acylation of the signal
sequence, MHC class I presentation and interaction of the antigen
with Toll-like receptor 2, which are processes that promote
induction of HIV-specific CD8+ T cells [35]. A recent study
comparing Gag-specific responses when expressed by wild type
BCG and the DpanCD auxotroph indicated that while clearance of
the bacteria occurred at the same rate, there was far less tissue
damage, less inflammation and less granuloma formation with the
DpanCD auxotroph which is a favourable factor for the use of the
auxotroph [5]. In this study, higher inflammation generated by the
wild type strain of BCG may also have inhibited the development
of the response to the subdominant epitopes after the rMVA boost.
IFN-c ELISPOT results indicated that delaying the time of the
rMVA booster vaccine to day 56 increased the immune response
to subdominant epitopes (data not shown), which probably arises
due to a time dependent decrease in the overall activation of the
immune system by innate BCG immune responses. It is also
possible that use of the BCGDpanCD vector results in higher and
more sustained production of the expressed proteins and thus
development of the immune response to subdominant epitopes.
The ability of vaccines to induce responses to multiple HIV
proteins is desirable with the broad immune responses increasing
the possibility of overcoming immune escape. HIV-specific CD4+
and CD8+ T cells recognising HIV-dominant and subdominant
epitopes were detected after a prime with a mix of BCGDpanCD
expressing either Gag, RT or Gp120 proteins and a boost with
rMVA. Higher inflammatory responses generated when using a
dose of 36107 cfu may account for the lower total IFN-c
ELISPOT responses achieved with the vaccine mix when
compared to the sum of the responses to the individual vaccines
Figure 5. Th1 cytokines induced by a prime with the individual rBCG-HIV vaccines or a mix of the rBCG-HIV vaccines and rMVA
boost. Groups of mice were primed with either the individual rBCGpan-Gag, rBCGpan-RT or rBCGpan-gp120 vaccines (107 cfu) or a rBCG vaccine mix
(36107 cfu) prepared by mixing 107 cfu of the individual vaccines rBCGpan-Gag, rBCGpan-RT and rBCGpan-gp120. Groups of mice vaccinated with
the BCGpan-Control vaccine (107 cfu to act as control for the individual vaccine vaccinations or 36107 cfu to act as control for the mix of the
individual vaccine vaccinations) served as controls. All groups of mice were then boosted with rMVA (104 pfu) on day 28. On day 40 spleens were
harvested and splenocytes pooled from 5 mice per group were stimulated with Gag, RT, Env and peptide H CD8+ T cell and CD4+ T cell peptides.
Culture supernatants collected at 48 h were analyzed for IFN-c (A), TNF-a (B) and IL-2 (C) using a cytokine bead array assay and flow cytometric
analysis. Data was expressed as pg cytokine/106 splenocytes. Bars are the average and standard deviation of the average cytokine released into the
supernatant during stimulation with the indicated individual peptide for 3 separate experiments. Statistical significance (Student’s t-test for means of
unpaired data) of the mean cytokine response for the individual peptides compared to that for the control is indicated.
doi:10.1371/journal.pone.0071601.g005
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used at a dose of 107 cfu. It is also possible that the simultaneous
presentation of HIV antigens by the vaccine mix and thus a
presentation of a broader repertoire of HIV epitopes than with an
individual vaccine, contributes to the observed lower immune
responses induced by the vaccine mix. However it is of importance
to note that the vaccine mix induced a broad T cell immune
response which is a desirable attribute of a vaccine. High levels of
CD8+ and CD4+ T cells recognising both subdominant and
dominant epitopes in Gag, RT and Gp120 that produced IFN-c
and TNF-a as well as CD4+ T cells that produced IL-2 were
generated. Vaccine-specific CD4+ T cells producing IL-2 are a
desirable outcome of vaccination as these cells are now understood
to be preserved in response to infection and to participate in
suppression of viremia levels post infection [36–38]. In this study
CD4+ cell produced IL-2 production may have provided help for
the induction of the HIV-specific CD8+ T cells.
A number of different studies have shown that recombinant
mycobacteria expressing HIV-1 antigens prime the immune
system for a heterologous booster vaccine. Macaques vaccinated
with rBCG-SIVgag and boosted with a replication deficient
vaccinia virus expressing SIV Gag were protected against a
mucosal challenge with pathogenic SHIV [9]. In another study
monkeys vaccinated with BCG expressing HIV-1 Gag, Pol and a
truncated Env elicited a robust, polyfunctional CD8+ T cell
response following a boost with Ad5 [4]. Tomas Hanke’s group
have shown, in a number of different studies, that a BCG.HIVA
prime followed by a boost with a viral vector expressing the HIVA
immunogen, can induce stable, robust, HIV-specific T cell
responses [6–8,31]. The rBCG vaccines utilised in this study were
able to prime the immune system for a boost with rMVA
expressing matching antigens, inducing HIV-specific T cells to
both dominant and subdominant epitopes in the individual
proteins in BALB/c mice, when used as individual vaccines or
in a mix. The expressed HIV proteins contained BALB/c mouse
MHC-I H-2Kd and H-2Dd as well as MHC-II restricted epitopes
which allowed detection of epitopic breadth of vaccine elicited T
cells to be determined. Further studies using these vaccines are
currently being carried out in non-human primates.
Although the induction of HIV-specific polyfunctional memory
cells was not enumerated in this study data from other studies has
indicated that BCG shows great promise as an HIV vaccine which
can elicit a broad, robust, polyfunctional T cell response when
used as a prime with a heterologous boost. In addition it is cheap
to produce, has a good safety record and could be used as a
combined vaccine against both HIV and TB. However, BCG can
cause disseminated disease in immunocompromised individuals.
Thus as BCGDpanCD is safer than wild type BCG in SCID mice,
causes less tissue damage in mice, shows attenuated growth in vivo
and gives a broad HIV-specific T cell response to the insert when
used as a vaccine vector without compromise of BCG-specific
immune responses (data not shown), BCGDpanCD may be a
suitable HIV vaccine vector for use in immunocompromised
individuals.
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